Instrument Inactif

Communiqués PERE PHARP Nasdaq

Actions

US7136614036

Communiqués

09/07/18	Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2018 After Market Close on July 16, 2018	GL
25/06/18	Avid Bioservices Added to Russell 3000® Index and Russell 2000® Index	GL
29/05/18	Avid Bioservices to Participate at BIO International Convention 2018	GL
08/05/18	Avid Bioservices Announces Appointment of Magnus Schroeder, Ph.D., as Vice President of Process Sciences	GL
24/04/18	Avid Bioservices Provides Update on Ongoing Expansion of Process Development Capabilities and Laboratory Infrastructure	GL
09/04/18	Avid Bioservices to Participate at INTERPHEX 2018	GL
13/03/18	Avid Bioservices to Participate at Upcoming CDMO Industry Conferences	GL
12/03/18	Avid Bioservices Reports Financial Results for Third Quarter of Fiscal Year 2018 and Recent Developments	GL
07/03/18	Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock	GL
06/03/18	Avid Bioservices to Present at the 30th Annual ROTH Conference	GL
05/03/18	Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2018 After Market Close on March 12, 2018	GL
01/03/18	Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of Novel Alzheimer’s Disease Candidate	GL
26/02/18	Avid Bioservices Announces Resignation of Chief Financial Officer	GL
21/02/18	Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant Sciences	GL
20/02/18	Avid Bioservices Announces Closing of Public Offering of Common Stock	GL
15/02/18	Avid Bioservices Announces Pricing of Public Offering of Common Stock	GL
14/02/18	Avid Bioservices Announces Proposed Offering of Common Stock	GL
12/02/18	Avid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid’s PS-Targeting Program Including Bavituximab	GL
23/01/18	Avid Bioservices to Present at NobleCon14	GL
05/01/18	Peregrine Pharmaceuticals Announces Name Change to Avid Bioservices as Part of Transition to Dedicated Contract Development and Manufacturing Organization (CDMO)	GL
02/01/18	Peregrine Pharmaceuticals to Present at Biotech Showcase 2018	GL
26/12/17	Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D., as President and Chief Executive Officer	GL
11/12/17	Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent Developments	GL
07/12/17	Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock	GL
04/12/17	Peregrine Pharmaceuticals to Report Financial Results for Second Quarter of Fiscal Year 2018 After Market Close on December 11, 2017	GL